Introduction
▼ Diabetes mellitus (DM) is the fourth or fi fth leading cause of death in most developed countries ( Richard et al., 2013 ) . In many developing countries, there is substantial evidence showing that its prevalence is growing ( Richard et al., 2013 ) . Despite advancement in diabetes diagnosis, prevention, and treatment, in 2011, 34 million patients had diabetes worldwide ( WHO, 2013 ) . Diabetes complications could lead to disability, reduced quality of life, and death. In 2011, 4.6 million patients died of this disease ( Richard et al., 2013 ) . Clinical manifestations of diabetes complications vary for diff erent people; it may aff ect various parts of the body. In addition, no internationally agreed standards exist for diagnosing and assessing diabetes complications. Diabetic neuropathy is a common serious complication of diabetes. Zucker diabetic fatty rats, type 1 insulinopenic BB/Wor and type 2 hyperinsulinemic diabetic BBZDR/Wor rats, nonobese diabetic, Akita mice, and leptin-and leptin-receptor-defi cient mice. Some techniques have been used to assess the behavioral responses to external stimuli in diabetic animals (i. e., thermal and mechanical hyper-and hypoalgesia, tactile allodynia, as well as formalininduced spontaneous nociceptive behavior). This review focuses on the discussion of selected animal models that have been proven to be useful in studying the underlying mechanisms of diabetic neuropathic pain.
Streptozotocin-Induced Diabetic Rats and Mice ▼ Streptozotocin (2-deoxy-2(3-methyl-3-nitrosoureido)-D-glucopyranose) is a nitrosourea analogue. It is toxic to the pancreatic insulin-secreting β-cells by damaging its DNA ( Szkudelski 2001 ; Lenzen et al., 2008 ) . It is similar to glucose and could be transported via glucose transporter GLUT2. The nitrosoamide moiety of streptozotocin is responsible for its toxicity. The establishment of streptozotocin-induced diabetes model is relatively simple, with one time injection either intraperitioneally or intravenously. Therefore, the streptozotocin-induced diabetic rat has been widely used to study mechanism of diabetic neuropathic pain and to evaluate potential therapies. Various doses of streptozotocin (35-200 mg/kg in rats or mice) have been studied in animal models ( Srinivasan, Ramarao 2007 ; Jafarnejad et al., 2008 ) . The susceptibility of animal to streptozotocin depends on age, species, and strain. Diff erent dosages may lead to diff erent levels of β-cell impairment in pancreas. Higher dose streptozotocin injection induced diabetes is similar to type I insulin-dependent diabetes in humans: within 72 h of injection, most rats become hyperglycemic, lowered glucose-stimulated insulin secretion, and decreased glucose intolerance. In about 4 1/2 weeks after injection, streptozotocin-treated rats exhibit behavioral signs of diabetic neuropathic pain, including signifi cant reduction in the withdrawal threshold to mechanical pressure and the latency to withdrawal from a noxious thermal stimulus ( Morrow, 2004 ) . Animal model of type 2 diabetes has been induced by combination of streptozotocin and nicotinamide (NA) administration in adult rats. NA is administrated to partially protect insulinsecreting β cells against streptozotocin. The protective mechanism is thought to partially due to the inhibition of PARP-1 activity, preventing depletion of NAD + and ATP in the cells exposed to streptozotocin. The severity of diabetes in this animal model depends on the doses of streptozotocin and NA. The hyperglycemia level could range from mild to severe ( Szkudelski, 2012 ). Interestingly, studies showed that a single injection of streptozotocin (80-100 mg/kg) into neonatal rats or immediately after birth, those rats will develop type II diabetes in the adult age ( Bonner-Weir et al., 1981 ; Portha et al., 1994 ) . Rats with shortterm diabetes develop neuropathic pain, whereas those with longer-term diabetes and diabetic mice typically display manifestations of both painful and insensate neuropathy, or insensate neuropathy only ( Obrosova, 2009 ). Thermal hyperalgesia is an increased sensitivity to pain, which may be caused by damage to nociceptors or peripheral nerves. It has been studied in streptozotocin induced animals with shortterm mechanisms have been identifi ed to be related to increased aldose reductase (AR), protein kinase C (PKC), poly (ADP-ribose) polymerase (PARP), angiotensin converting enzyme (ACE) activities, toll-like receptor 4, and oxidative stress ( Meller et al., 1992 ; Cotter et al., 2002 ; Obrosova et al., 2008 ; Yan et al., 2012 ) . It was shown that subsequent activation of soluble guanylate cyclase in the lumbar spinal cord could mediate thermal hyperalgesia. Increased excitability of dorsal root ganglion neurons and expression of Nav1.7 and p-EPK1/2 has been identifi ed in thermal hyperalgesia ( Zhang et al., 2013 ) . In addition, methylglyoxal treatment for thermal hyperalgesis could induce post-translational modifi cation of the nociceptor-specifi c sodium channel Nav 1.8, reduce nerve conduction velocity, neurosecretion of calcitonin gene-related peptide, and increase cyclooxygenase-2 (COX-2) expression ( Bierhaus, Nawroth 2012 ). In a chemical hyperalgesia induced by formalin in streptozotocin animal model, it has also been shown that peripheral activation of CB1 and CB2 receptor mediate the antinociceptive eff ect of exogenous and endogenous anandamide ( Schreiber et al., 2012 ) . Thermal hypoalgesia occurs when nociceptive stimuli are interrupted or decreased in the pathway. It is a clinical manifestation in patients with advanced diabetic neuropathy. This condition has been studied in long-term streptozotocin-induced diabetes models ( Overall, steptozotocin-induced diabetic animal models have been widely studied to understand diabetic neuropathic pain. The mechanism underlying hyperalgesia and abnormal sensation were identifi ed as increased AR activity, oxidative-nitrosative stress, protein kinase C, PARP and ACE activations, C-peptide defi ciency, impaired neurotrophism, and proinfl ammatory response ( Increased proinsulin to insulin ratio in pancreatic β cells was shown. Insulin support was required for survival of Sand rats at a late stage. In C57BL/6 J ( ob/ob ) mouse, onset of symptoms is genetically determined. When treated orally with, LAF237, an inhibitor of dipeptidyl peptidase-IV, these mice showed normalized glucose tolerance in association with augmented insulin secretion ( Winzell, Ahren 2004 ).
In addition, Acomys calirinus (spiny mouse) showed weight gain and pancreatic β cell hyperplasia, hypertrophy and increased pancreatic insulin content when on high energy diet. An impairment hormone release mechanism was demonstrated in these mice ( Velasquez et al., 1990 ) . These mice develop frank hyperglycemia with glucosuria leading to fatal ketosis. Diet/nutrition induced diabetic animal models have been studied for diabetic neuropathic pain. It was shown that a high-fat diet-fed mouse manifested alimentary obesity, hyperinsulinemia, and impaired glucose tolerance, leading to nerve conduction velocity defi cit and small sensory fi ber neuropathy, as well as increased sorbitol pathway activity, oxidative-nitrosative stress, and pro-infl ammatory changes in PNS. More specifi cally, increased lipoxygenase activity has been implicated in endothelial dysfunction, an important factor in motor and sensory nerve conduction velocities defi cits that associated with both diabetic and prediabetic neuropathy. In addition, lipoxygenase has been shown to be involved in high-fat-diet-induced infl ammation A major limitation to this approach is that most diet/nutrition induced diabetes animal models required long period time for induction. Therefore, these models are considered as long-term high-fat diet models.
Models Induced by Combination of Diet/Nutrition and Streptozotocin
▼ Various studies showed the benefi ts of using the combination of nutrition-and streptozotocin-induced animal model. By using a combination of a high-fat diet and a streptozotocin inducer, diabetes can be induced more quickly. Diff erent levels of high-fat diet and streptozotocin combinations have been studied. 
Zucker diabetic fatty rat model
The Zucker diabetic fatty (ZDF) is an outbred rat model that spontaneously progresses to frank diabetes due to failure to compensate adequately for insulin resistance. The homozygous mutation ( fa/fa ) of the leptin hormone receptor is involved in the development of type 2 diabetes in male rats when they are fed a high-energy rodent diet ( Hemmes and Schoch, 1988 ). Obese ZDF rats could have high levels of triglyceride and cholesterol. By using high saturated fat and sucrose-containing diets, very high lipid levels can be induced. In ZDF rats, the pancreatic islets were shown to have increased intraislet expression of ACE and angiotensin type 1 as well as increased intraislet fi brosis, apoptosis, and oxidative stress ( Siwy et al., 2012 ) . In addition, examination of ZDF rat somatic (sciatic) nerve has shown evidence of neuropathy similar to streptozotocin-rats as characterized by reduced conduction velocity and morphological changes in myelinated axons ( Schmidt et al., 2003 ) . It was reported that increased ACE and hydroxymethylglutaryl-CoA reductase activities, and neutral endopeptidase might be involved in sensory loss in Zucker fatty rats ( Oltman et al., 2009 ; Oltman et al., 2008 ) .
BBZDP/Wor rat
In addition to encoding the Leprfa mutation in ZDF rats, the BBZDP/Wor strain carries the Iddm2 type 1 diabetes associated genetic locus ( Mordes et al., 2004 ) . BBZDP/Wor rats develop lymphopenia, obesity, hyperinsulinemia, and autoimmune diabetes ( Guberski et al., 1988 ) . It is believed that BBZDP/Wor rat develop diabetes due to a combination of insulin resistance and autoimmune insulitis. Therefore, both type 1 and type 2 diabetes characteristics exist in this model.
BBZDR/Wor rat
BBZDR/Wor type 2 diabetic rat was developed by crossing BBZDP/Wor animals with the lean, nondiabetic BBDR/Wor rats, in order to remove the recessive Iddm2 gene responsible for lymphopenia and spontaneous autoimmunity and retain the Leprfa ( fa 1) mutation. Therefore, the BBZDR/Wor rat is an inbred rat model for type 2 diabetes. BBZDR/Wor diabetic rat has been shown to have dyslipidemia, hyperglycemia, insulin resistance, hypertension, and decreased levels of the β cell-specifi c glucose transporter type-2 (GLUT-21) ( Ellis et al., 1998 ). Furthermore, reduction of GLUT-2 staining of β-cell surface membranes has been observed. The type 2 diabetic BBZDR/Wor and type 1 diabetic BBDP/Wor rat models have been studied for diabetic neuropathy. These 2 models show similarities and diff erences of disease pathogenesis. Progressive reduction of nerve conduction velocity, axonal atrophy, and degeneration, inactivation of Na + -channels, intraaxonal Na + accumulation at the node, decreased Na + /K + -ATPase, and nerve degeneration have been evident in both models. However, the slowing of nerve conduction velocities has been shown to be more severe in BBZDP/Wor rats than in BBZDR/Wor rats. On the other hand, BBZDR/Wor rats display a more severe Na + /K + -ATPase defect. In BBZDP/Wor type 1 diabetes, disruption of the paranodal ion-channel barrier by axoglial dysjunction and paranodal demyelination have been demonstrated. While in BBZDR/Wor rats with type 2 diabetes, these structural changes have not been observed. Also, studies have shown that the perturbed insulin signaling due to insulin and/or C-peptide defi ciency in type 1 BBDP/Wor rats may account for the diff erences seen between these 2 diabetic models ( Sima and Sugimoto, 1999 ; Sima et al., 2000 ) . While in BB/Wor type 2 diabetes model, whole-cell, high-threshold, voltage-dependent calcium currents were enhanced in acutely dissociated, capsaicin-sensitive dorsal root ganglion neurones ( Hall et al., 1995 ) . In a mechanical allodynia type 2 diabetic ZDF model, activation of CB1 has been shown to be involved in cannabinoid-induced relief of neuropathic pain ( Obrosova et al., 2007 ) . Another interesting fi nding is the reduced intraepidermal nerve fi ber density in ZDF models ( Oltman et al., 2008 ) .
Transgenic/Knock-out Diabetic Models ▼ It has been shown that the behavioral changes of neuropathic pain in transgenic/knock-out diabetic models are strongly infl uenced by the specifi c knock-down of certain receptors such as the P2 X 3 receptor. In one animal model, 7 days after spinal nerve ligation, interestingly, the P2 X 3 receptor expression was decreased in small diameter neurons of the L5-L6 DRG. However, the increase was not found in large diameter neurons in L5-L6 DRG as well as in both small and large diameter neurons in L4 DRG. Inhibitor RNA (iRNA) techniques may be used in future studies to reduce the compensatory genetic alternatives in knock-out animals ( Kage et al., 2002 ) .
Limitations

▼
Currently, available treatments for diabetic neuropathic pain are far from eff ective. Diabetic animal models have been widely used to identify new targets for diabetic neuropathic pain treatment. Even though models for studying diabetic neuropathic pain has identifi ed a number of pathogenetic mechanisms implicated in diabetic painful and insensate neuropathy, the current models still have some limitations for diabetic neuropathic pain studies. Firstly, the life span of animal models is limited without obvious neuropathy. It is especially challenging to study how demyelination, axonal degeneration, fi ber loss, or axonal regeneration contribute to diabetic neuropathic pain develop and progress. In addition, quantifi cation of spontaneous pain in animals is technically challenging. Combination of multiple modalities, including streptozotocin and diet-nutrition, may be able to produce a more sophisticated animal model for diabetic neuropathic pain. In addition, gene expression profi ling was explored for changes in mRNA transcripts in the dorsal root This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
ganglia and dorsal horn across multiple models of peripheral neuropathic pain. Further, sophisticated tools that have been developed and used in clinical studies including quantitative measurement of symptoms and signs and quantitative sensory testing may be adapted into animal models ( Tegeder et al., 2006 ; Bennett et al., 2007 ; Hansson et al., 2007 ) .
In conclusion, various animal models have been used to understand the mechanism underlying pathogenesis of diabetic neuropathic pain ( • ▶ Table 1 ). Some commonly shared pathways have been identifi ed in the development of diabetic neuropathic pain, including increased AR, PKC, and PARP activities, nonenzymatic glycation/glycoxidation, and oxidative stress. However, pathogenesis of painful diabetic neuropathy is still waiting for further investigations. Identifying particular neurobiological mechanisms contributing to neuropathic pain in individuals and development of more sophisticated tools for measuring and categorizing neuropathic pain may advance the progress of diabetic neuropathic pain animal models.
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